secwatch.observer — SEC 8-K summary
======================================

Issuer:     Third Harmonic Bio, Inc. (—)
CIK:        0001923840
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-138910
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

THRD reports Q1 net loss $7.9M; FDA clears THB335 IND; Phase 1 trial initiated
------------------------------------------------------------------------------

- Cash $262.8M as of Mar 31, 2024; expected to fund operations through at least 2026.
- Net loss $7.9M for Q1 2024 vs $9.1M in Q1 2023; R&D expense $6.2M, G&A $5.1M.
- FDA cleared IND for THB335 (oral KIT inhibitor); Phase 1 SAD/MAD trial initiated, results expected 1H 2025.
- Leadership: Christopher Dinsmore CSO, Dennis Dean Chief Non-Clinical Dev Officer, Jennifer Dittman promoted to Chief Dev Ops Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1923840/000119312524138910/0001193125-24-138910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1923840/000119312524138910/d840135d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer